Epitope editing shields healthy blood cells from immunotherapies
Source: Drug Discovery News, April 2024
Monoclonal antibodies and immunotherapy are potent cancer treatments, but preventing treatment resistance to these therapies is challenging.
Monoclonal antibodies fail to engage T cells for sustained antitumor immunity, and immunotherapy does not account for antigen variation across malignant cells. Bispecific antibodies offer a solution by bolstering T cell action against cancer cells and simultaneously targeting distinct antigens. In this webinar, George Weiner will discuss combining anticancer monoclonal and bispecific antibodies to enhance T cell help, and Mohamed-Reda Benmebarek will delve into using adaptable, bispecific antibodies to address antigen variability while ensuring sustained clinical efficacy.
Topics to be covered
- Exploiting the synergistic power of bispecific and monoclonal antibodies
- Developing bispecific antibodies for modular and controllable cancer therapy